|
|
|
|
|
|
||||
|
|
 |
|
|
|
 |
||||||||||||||||||||||||||||||||||||||||||
|
 |
||||||||||||||||||||||||||||||||||||||||||||||
History & Intellectual Property |
|||||||||||||||||||||||||||||||||||||||||||||||
|
Gyros was founded in 2000 as a spin-out of Amersham Pharmacia
Biotech (now GE Healthcare). Today, Gyros has more than 15 years of research
and development experience in surface chemistry, microfluidics, microfabrication,
software, system integration and assay development.
Gyros holds a strong intellectual property position, with more than 75 patent families, covering approximately 80 inventions and 29 issued US patents. In 2004, Gyros launched products for the protein therapeutics instrument market, aimed at superseding automated ELISA systems in terms of applicability, performance and quality. In the same year, the Company also entered into a collaborative IVD development project with Fujirebio Inc., Japan. Outside current strategy, Gyros has established proof-of-concept in other application areas such as high throughput screening, automated cell handling, molecular diagnostics and mass spectrometry. |
|
|||||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||||||
| Home page Web Map Legal notice | |||||||||||||||||||||||||||||||||||||||||||||||
